- Report
- December 2023
- 91 Pages
Global
From €5717EUR$5,950USD£4,916GBP
- Report
- May 2024
- 898 Pages
Global
From €5381EUR$5,600USD£4,627GBP
- Report
- November 2023
- 173 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- January 2024
- 200 Pages
Global
From €3988EUR$4,150USD£3,429GBP
- Report
- September 2021
- 40 Pages
China
From €2498EUR$2,600USD£2,148GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21139EUR$22,000USD£18,177GBP
- Report
- April 2018
Global
From €961EUR$1,000USD£826GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£826GBP
- Report
- January 2022
- 137 Pages
Global
From €4324EUR$4,500USD£3,718GBP
Keppra is a brand name of the antiepileptic drug levetiracetam, which is used to treat epilepsy and other seizure disorders. It is a member of the Central Nervous System (CNS) drug class, which includes drugs used to treat neurological conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Keppra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial onset seizures in adults and children aged four years and older. It is also approved for the treatment of myoclonic seizures in adults and children aged 12 years and older.
Keppra is available in both oral and intravenous formulations. It is marketed by UCB, Inc., a biopharmaceutical company based in Belgium. Other companies that market levetiracetam include Mylan Pharmaceuticals, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more
